EGFR and lung carcinoma: These findings underscore the prognostic value of both a serum biomarker (CEA) and metastatic pattern (particularly brain involvement), while also supporting the survival benefit of first‐line EGFR‐TKI therapy in patients with stage IV lung cancer.